Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Angle Plc ADR
(OP:
ANPCY
)
1.847
UNCHANGED
Last Price
Updated: 3:32 PM EST, Feb 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Angle Plc ADR
< Previous
1
2
3
4
5
Next >
Angle PLC Announces Notice of Interim Results and Webcast
September 07, 2021
GUILDFORD, SURREY / ACCESSWIRE / September 7, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 30 June 2021...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Director/PDMR Shareholding
August 24, 2021
ANGLE plc ('ANGLE' or the 'Company') Director/PDMR Shareholding Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / August 24, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC - Study Highlights Superior Performance of Parsortix
August 09, 2021
PUBLICATION HIGHLIGHTS EASE OF USE AND SUPERIOR PERFORMANCE OF PARSORTIX SYSTEM IN HARVESTING CTCs FROM METASTATIC BREAST CANCER PATIENTS Quantity, purity and quality of CTCs captured using the...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Issue of Equity
August 06, 2021
Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / August 6, 2021 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Issue of Equity
August 03, 2021
Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / August 3, 2021 / ANGLE plc (OTCQX:ANPCY) (AIM:AGL), a world-leading liquid biopsy company, announces that following the...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Contract Secured For Bespoke Assay Development
July 28, 2021
ANGLE to develop two custom CTC assays to look at biomarkers of DNA damage repair Validated assays expected to be used for longitudinal analysis in clinical trial GUILDFORD, SURREY / ACCESSWIRE / July...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Harvesting CTCs from Brain Metastasis Patients
July 09, 2021
PARSORTIX USED TO SUCCESSFULLY HARVEST CANCER CELLS FOR ANALYSIS FROM THE BLOOD OF PATIENTS WITH BRAIN METASTASIS Parsortix successful in overcoming challenges associated with isolating CTCs from brain...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Director/PDMR Shareholding
July 07, 2021
ANGLE plc Director/PDMR Shareholding Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / July 7, 2021 / ANGLE plc ('ANGLE' or the 'Company') (AIM:AGL) (OTCQX:ANPCY), a...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC announces Issue of Equity
July 02, 2021
Exercise of options and total voting rights GUILDFORD, UK / ACCESSWIRE / July 2, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Result of AGM
June 30, 2021
ANGLE plc ('the Company') Result of 2021 Annual General Meeting GUILDFORD, SURREY / ACCESSWIRE / June 30, 2021 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Annual General Meeting update
June 18, 2021
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, confirms that its Annual General Meeting (AGM) will be held as a closed meeting...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Angle PLC Announces ctDNA and CTCs have differences in EGFR mutations
June 18, 2021
- DIFFERENCES FOUND IN EGFR MUTATIONS BETWEEN ctDNA AND CTCs IN MATCHED LIQUID BIOPSIES FROM NON-SMALL LUNG CANCER PATIENTS - Study supports analysis of CTCs, together with ctDNA, from serial liquid...
From
ANGLE plc
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Product Safety
Angle PLC Announces Update on Submission for FDA Clearance
June 04, 2021
UPDATE ON SUBMISSION FOR FDA CLEARANCE OF THE PARSORTIX SYSTEM Response to Additional Information Request made to FDA as planned GUILDFORD, UK / ACCESSWIRE / June 4, 2021 / ANGLE plc...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Potential to Prevent Breast Cancer Relapse
June 01, 2021
BREAKTHROUGH RESEARCH SUPPORTS POTENTIAL USE OF PARSORTIX IN PREVENTION OF RELAPSE OF BREAST CANCER PATIENTS IN REMISSION Parsortix system successfully used to harvest cancer cells "hibernating" in the...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Parsortix Demonstrates Oesophageal Cancer Utility
May 20, 2021
- Parsortix system consistently harvests CTCs of high quality - Research paves the way for downstream molecular analysis to enable targeted treatment in this hard-to-treat cancer GUILDFORD, UK /...
From
ANGLE plc
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Product Safety
Angle PLC Announces Exercise of options and total voting rights
May 19, 2021
GUILDFORD, SURREY / ACCESSWIRE / May 19, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
May 11, 2021
- Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets - Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Exercise of Options and Total Voting Rights
April 30, 2021
SURREY, UK / ACCESSWIRE / April 30, 2021 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Preliminary Results
April 29, 2021
ANGLE plc ("ANGLE" or "the Company") Preliminary Results for the year ended 31 December 2020 FDA SUBSTANTIVE REVIEW PROGRESSING LAUNCH OF CLINICAL LABORATORY SERVICES FIRST LARGE-SCALE CONTRACT WITH...
From
ANGLE plc
Via
AccessWire
Exposures
COVID-19
Product Safety
Angle PLC- Ovarian Cancer Study Patient Enrolment Completed
April 26, 2021
PATIENT ENROLMENT COMPLETED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY Headline results from the Study expected in Q4 2021 Study designed to support launch of an ovarian cancer test from ANGLE's...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces First Large-Scale Pharma Services Contract Secured
April 16, 2021
- Contract Worth Up to US$1.2 Million With Potential for Further Contracts From the Same Customer - Parsortix System Being Utilised in Cancer Drug Trials for Liquid Biopsy Longitudinal Monitoring Which...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Angle PLC Announces Notice of Preliminary Results and Webcast
April 15, 2021
GUILDFORD, SURREY / ACCESSWIRE / April 15, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2020...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
ANGLE's Parsortix system showcased at AACR 2021
April 12, 2021
ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021...
From
ANGLE plc
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.